AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$AHCO

Schuster III Russell E. sold $113K of AHCO

Schuster III Russell E. (Chief Commercial Officer) sold 11,275 shares of AdaptHealth Corp. (AHCO) at $10.06 ($0.11M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schuster III Russell E.
Published Jun 3, 2026, 10:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 10:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AHCO
Neutral
high confidence
Mentioned
$AHCO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AHCONeutralLow
01

Why it matters

Focus is on whether the sale is scheduled (10b5-1) and whether it meaningfully changes the risk/reward for AHCO holders; no new business developments are provided.

02

Market read

A scheduled insider sale is disclosed; traders may monitor for follow-on insider buying/selling patterns, but this filing alone is unlikely to drive a major repricing.

03

What to watch

Insider sales often reflect diversification or scheduled selling; without changes in buying activity or new disclosures, signal strength is limited.

Relevance 6/10Novelty 3/10Timing: After-hours/filing update on 2026-06-03 for a 2026-06-01 sale

Background

The article is an SEC Form 4 insider transaction (officer sale) for AdaptHealth, reported via EDGAR.

Company-level read

Ticker impact

$AHCONeutralHigh confidence
Context

AdaptHealth CCO Russell E. Schuster III sold $113,426 of AHCO shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted given the disclosed 10b5-1 plan.

Evidence & confidence

The filing is a routine insider sale with a pre-arranged 10b5-1 plan and no accompanying operational or financial catalyst.

Market effects

Sector

Minimal; single-company insider sale with no sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can still coincide with internal expectations of near-term liquidity needs, but it is not strong evidence of deteriorating fundamentals.

Key entities

  • issuer
    AdaptHealth Corp.

    Subject of the SEC Form 4 insider sale disclosure.

  • insider
    Schuster III Russell E.

    Chief Commercial Officer who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AHCO insider trading history →

Related articles

SEP 9
$AHCOMed

Why AdaptHealth (AHCO) Stock Is Down Today

AdaptHealth (AHCO) shares fell 8.6% after announcing Harriss T. Currie as CFO, replacing Jason Clemens. The company reported a Q2 loss of $0.99 per share, missing estimates, and cut 2026 revenue guidance to $2.87B. The stock is down 41.6% YTD and 57.8% from its 52-week high.

financialcontent.com2 min
AUG 15
$AHCOMedAI 8/10

AdaptHealth Cuts 2026 Outlook as Contract Costs Hit Margins

AdaptHealth Corp. (AHCO) cut its 2026 adjusted EBITDA outlook to $490 million to $520 million from $680 million to $730 million, citing margin pressure from West Coast capitated contract costs and a manufacturer price increase. Revenue guidance is $2.85 billion to $2.89 billion. Q2 organic revenue rose 15.9% to $740.3 million. The company agreed to sell Diabetes Health for $235 million.

mychesco.com6 min
AUG 11
$AHCOHighAI 9/10

AdaptHealth (AHCO) Q2 2026 Earnings Call Transcript

AdaptHealth (AHCO) reported Q2 2026 net revenue of $740.3 million, up 12.7% year over year, with organic revenue growth of 15.9%. Adjusted EBITDA was $132 million, down 3.2%, and full-year revenue guidance was cut to $2.85-$2.89 billion with adjusted EBITDA of $490-$520 million. The company cited West Coast contract costs and a $30 million supplier price headwind, plus a $235 million diabetes divestiture.

fool.com7 min
AUG 11
$AHCOMed

AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth

AdaptHealth (NASDAQ:AHCO) said it will sell its diabetes unit to focus on sleep and respiratory. The deal is expected to leave about $60 million of overhead costs in continuing operations, with roughly half removed in year one. Q2 revenue grew 16%, including West Coast expansion, while the company works on contract onboarding and supplier rebate terms.

yahoo.com6 min
AUG 9
$AHCOHighAI 9/10

Why AdaptHealth Stock Plummeted This Week

AdaptHealth (NASDAQ: AHCO) shares fell about 47% this week after the company reported Q2 results below expectations and issued sharply lower guidance. Analysts expected EPS of $0.15; AdaptHealth posted a loss of $1.07 per share. Sales rose 12.7% to $740.3M but missed forecasts. Full-year sales guidance was cut to $2.85B-$2.89B and EBITDA and FCF ranges were reduced.

yahoo.com2 min